Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Cellebrite DI, with five buys and one sell among six analysts. The average 12-month price target is $16.70, although several firms recently lowered their targets.
• Shares opened at $11.99, near the lower end of their 52-week range of $9.58 to $19.98, while the 50-day and 200-day moving averages stood at $14.16 and $13.77, respectively.
• Insiders sold 329,658 shares worth approximately $4.97 million over the past three months, while institutional investors own 45.88% of the company and several funds recently increased their positions.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $16.70.

A number of equities analysts have recently weighed in on CLBT shares. JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a research note on Friday, August 14th. DA Davidson reduced their price objective on Cellebrite DI from $22.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Needham & Company LLC lowered their target price on Cellebrite DI from $15.00 to $12.50 and set a "buy" rating on the stock in a research note on Friday, August 14th. Weiss Ratings lowered Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday. Finally, Lake Street Capital cut their price target on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, August 14th.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CFO David Barter sold 41,734 shares of the business's stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the sale, the chief financial officer owned 334,219 shares of the company's stock, valued at $5,474,507.22. The trade was a 11.10% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Thomas E. Hogan sold 25,299 shares of the business's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total transaction of $285,625.71. Following the completion of the sale, the insider directly owned 765,249 shares in the company, valued at $8,639,661.21. This trade represents a 3.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 329,658 shares of company stock worth $4,970,967 over the last three months. 5.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cellebrite DI by 16.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company's stock worth $3,362,000 after buying an additional 24,881 shares in the last quarter. Geode Capital Management LLC raised its stake in Cellebrite DI by 16.2% during the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company's stock worth $5,029,000 after acquiring an additional 43,898 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Cellebrite DI by 6.4% during the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company's stock valued at $56,089,000 after acquiring an additional 209,473 shares during the period. First Trust Advisors LP acquired a new stake in shares of Cellebrite DI in the 2nd quarter valued at $341,000. Finally, Marshall Wace LLP acquired a new stake in shares of Cellebrite DI in the 2nd quarter valued at $4,472,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $11.99 on Monday. The firm has a market cap of $2.99 billion, a PE ratio of 54.50, a P/E/G ratio of 1.84 and a beta of 1.18. The firm's 50 day moving average price is $14.16 and its two-hundred day moving average price is $13.77. Cellebrite DI has a twelve month low of $9.58 and a twelve month high of $19.98.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.